[go: up one dir, main page]

EP1235576A2 - Combinaisons de sumatriptan ou de naratriptan avec l'inhibiteur de cyclooxygenase ii - Google Patents

Combinaisons de sumatriptan ou de naratriptan avec l'inhibiteur de cyclooxygenase ii

Info

Publication number
EP1235576A2
EP1235576A2 EP00979767A EP00979767A EP1235576A2 EP 1235576 A2 EP1235576 A2 EP 1235576A2 EP 00979767 A EP00979767 A EP 00979767A EP 00979767 A EP00979767 A EP 00979767A EP 1235576 A2 EP1235576 A2 EP 1235576A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
pharmaceutically acceptable
sumatriptan
inhibitor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979767A
Other languages
German (de)
English (en)
Inventor
Donna Gutterman
Reijo Juhani Salonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to EP05075041A priority Critical patent/EP1522305A1/fr
Publication of EP1235576A2 publication Critical patent/EP1235576A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • the present invention relates to the treatment of conditions associated with cephalic pain such as migraine, cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, headache associated with substances or their withdrawal and tension headache.
  • cephalic pain such as migraine, cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, headache associated with substances or their withdrawal and tension headache.
  • a 5HT ⁇ agonist in conjunction with a COX-2 inhibitor.
  • 5-HT r like receptors are located, for example, in the dog saphenous vein and the 5-HT like receptor agonists with which the present invention is concerned contract the dog saphenous vein. Such compounds may therefore be identified by their contractile effect on the dog isolated saphenous vein strip as described, for example, by Apperley et al., Br. J. Pharmacol, 68, 215-224 (1980). Compounds which are selective 5-HT r like receptor agonists have also been found to selectively constrict the carotid arterial bed of the anaesthetised dog.
  • a method of treating conditions associated with cephalic pain and alleviating the symptoms associated therewith comprises administering to a mammal, including man, a 5HT- I agonist or a pharmaceutically acceptable derivative thereof and 2- (4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1 ,5-b]pyridazine or a pharmaceutically acceptable derivative thereof.
  • a 5HT ⁇ agonist or a pharmaceutically acceptable derivative thereof 2-(4-ethoxy- phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1 ,5-b]pyridazine or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of conditions associated with cephalic pain and the alleviation of symptoms associated thereof.
  • pharmaceutically acceptable derivative any pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide, of the 5HT ⁇ agonist or the COX-2 inhibitor, or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) the 5HT ⁇ agonist or the COX-2 inhibitor or an active metabolite or residue thereof.
  • Suitable physiologically acceptable salts according to the invention include acid addition salts formed with inorganic acids such as hydrochlorides, hydrobromides, phosphates and sulphates and with organic acids, for example tatrates, maleates, fumarates, succinates and sulphonates.
  • inorganic acids such as hydrochlorides, hydrobromides, phosphates and sulphates
  • organic acids for example tatrates, maleates, fumarates, succinates and sulphonates.
  • Suitable 5HT ⁇ like receptor agoinsts include sumatriptan, naratriptan, zolmitriptan, rizatriptan, eletriptan, frovatriptan, almotriptan, alniditan, ALX-0646, LY334370, U 1092291 , IS159 and PNY142633. Naratriptan and sumatriptan are preferred with sumatriptan being particularly preferred.
  • a preferred form of sumatriptan is the succinate salt, particularly the 1 :1 succinate.
  • a method of treating conditions associated with cephalic pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man sumatriptan or a physiologically acceptable salt therefore and a 2-(4- ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1 ,5-b]pyridazine or a physiologically acceptable salt thereof.
  • Compounds for use according to the invention may be administered simultaneously or sequentially and, when administration is sequential, either the 5HT ⁇ agonist or the COX-2 inhibitor may be administered first.
  • Compounds for use according to the invention may be administered as the raw material but the active ingredients are preferably provided in the form or pharmaceutical formulations.
  • the active ingredients may be used either as separate formulations or as a single combined formulation. When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. Therefore, pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier or comprise a further aspect of the invention. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.
  • compositions which comprises a 51-1 ⁇ agonist or a pharmaceutically acceptable derivative thereof and a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof formulated for administration by any convenient route.
  • Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in conventional manner using one or more pharmaceutically acceptable carriers or exciplents.
  • the formulations include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) or in a form suitable for administration by inhalation or insufflation administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the compounds ("active ingredient") with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Preferably such compositions will be formulated for oral administration. It will be appreciated that when the two active ingredients are administered independently, each may be administered by different means.
  • Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric administration) each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in- oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a other conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, polyvinylpyrrolidone) or hydroxymethyl cellulose or hydroxymethyl cellulose fillers (for example, lactose, sugar, microcrystalline cellulose, tnaize- starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulfate.
  • binding agents for example, syrup, acacia, gelatin
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • the tablets may be coated according to methods well-known in the art.
  • the compounds of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example.
  • formulations containing these compounds may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl p- hydroxybenzoates or sorbic acid.
  • Such preparations may also be formulated as suppositories, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of a sterile liquid carrier, for example, water-for-injection, immediately prior to use.
  • a sterile liquid carrier for example, water-for-injection
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, hard fat or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • the compounds may be formulated as creams, gels, oiintments or lotions or as a transdermal patch.
  • the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneousiy or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be used, for example as a liquid spray, as a powder or in the form of drops.
  • the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. 1 ,1 ,1 ,2-trifluoroethane (HFA 134A) and 1 ,1 ,1 ,2,3,3,3, - heptapropane (HFA 227), carbon dioxide or other suitable gas.
  • a suitable propellant e.g. 1 ,1 ,1 ,2-trifluoroethane (HFA 134A) and 1 ,1 ,1 ,2,3,3,3, - heptapropane (HFA 227), carbon dioxide or other suitable gas.
  • HFA 134A 1 ,1 ,1 ,2,3,3,3,3, - heptapropane
  • COF carbon dioxide
  • Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • treatment extends to prophylaxis as well as the treatment of established diseases or symptoms.
  • amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
  • doses employed for adult human treatment will typically be in the range of 0.02- 5000 mg per day, preferably 1-1500 mg per day.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the formulations according to the invention may contain between 0.1-99% of the active ingredient, conveniently from 30-95% for tablets and capsules and 3-50% for liquid preparations.
  • compositions according to the invention may be prepared by conventional techniques. When combined in the same formulation for example, the 5HT ⁇ agonist or a pharmaceutically acceptable derivative thereof and COX- 2 inhibitor or a pharmaceutically acceptable derivative thereof may be admixed together, if desired, with suitable excipients. Tablets may be prepared, for example, by direct compression of such a mixture. Capsules may be prepared, for example by filling the blend together with suitable excipients into gelatin capsules, using a suitable filling machine.
  • compositions for use according to the invention may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the compounds are intended for administration as two separate compositions these may be presented, for example, in the form of a twin pack.
  • the dose at which the 5HT ⁇ agonist and the COX-2 inhibitor is administered will depend on the age and condition of the patient and the frequency and route of administration and will be at the ultimate discretion of the attendant physician.
  • the active ingredients may conveniently be presented in unit dose form.
  • a proposed dose of 5HT ⁇ agonist for administration to man (of approximately 70kg body weight) is 0.001 mg to 500 mg per unit dose which may be administered for example 1 to 4 times per day.
  • the COX-2 inhibitor may conveniently be administered at doses within the normal range taught in the art at which the compounds are therapeutically effective.
  • a proposed dose of the COX-2 inhibitor for use according to the invention is 0.001 to 500mg, preferably 0.01 to 100mg, most preferably 0.05 to 50mg, for example 0.5 to 25mg mg per unit dose, expressed as the weight of free base.
  • the unit dose may be administered in single or divided doses, for example, from 1 to 4 times per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de traitement d'états associés aux douleurs céphaliques et soulageant les symptômes associés, consistant à administrer un agoniste du 5HT1 ou un sel ou solvat physiologiquement acceptable de cet agoniste et de la 2-(4-éthoxy-phényl)-3-(4-méthanesulfonyl-phényl)-pyrazolo[1,5-b]pyridazine ou un sel ou solvat physiologiquement acceptable de ce composé à un mammifère, y compris l'homme.
EP00979767A 1999-12-08 2000-11-28 Combinaisons de sumatriptan ou de naratriptan avec l'inhibiteur de cyclooxygenase ii Withdrawn EP1235576A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05075041A EP1522305A1 (fr) 1999-12-08 2000-11-28 Combinaisons de sumatriptan avec un inhibiteur de la cyclooxygénase ii

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9929039.7A GB9929039D0 (en) 1999-12-08 1999-12-08 Medicaments
GB9929039 1999-12-08
PCT/GB2000/004532 WO2001041749A2 (fr) 1999-12-08 2000-11-28 Formulations d'agonistes du 5ht

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05075041A Division EP1522305A1 (fr) 1999-12-08 2000-11-28 Combinaisons de sumatriptan avec un inhibiteur de la cyclooxygénase ii

Publications (1)

Publication Number Publication Date
EP1235576A2 true EP1235576A2 (fr) 2002-09-04

Family

ID=10865954

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00979767A Withdrawn EP1235576A2 (fr) 1999-12-08 2000-11-28 Combinaisons de sumatriptan ou de naratriptan avec l'inhibiteur de cyclooxygenase ii
EP05075041A Withdrawn EP1522305A1 (fr) 1999-12-08 2000-11-28 Combinaisons de sumatriptan avec un inhibiteur de la cyclooxygénase ii

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05075041A Withdrawn EP1522305A1 (fr) 1999-12-08 2000-11-28 Combinaisons de sumatriptan avec un inhibiteur de la cyclooxygénase ii

Country Status (5)

Country Link
EP (2) EP1235576A2 (fr)
JP (1) JP2003516349A (fr)
AU (1) AU1715901A (fr)
GB (1) GB9929039D0 (fr)
WO (1) WO2001041749A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3035980A1 (fr) 2013-08-19 2016-06-29 Dr. Reddy's Laboratories Ltd. Auto-injecteur à dose unique sélectionnable et procédés de fabrication et d'utilisation associés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
WO2000048583A2 (fr) * 1999-02-19 2000-08-24 Pozen Inc. Formulation d'agonistes de 5-ht et d'inhibiteurs de cox-2
AU3253800A (en) * 1999-05-14 2000-11-16 Pfizer Products Inc. Combination therapy for the treatment of migraine
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
AU6917400A (en) * 1999-08-31 2001-03-26 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0141749A2 *

Also Published As

Publication number Publication date
EP1522305A1 (fr) 2005-04-13
GB9929039D0 (en) 2000-02-02
AU1715901A (en) 2001-06-18
WO2001041749A2 (fr) 2001-06-14
JP2003516349A (ja) 2003-05-13
WO2001041749A3 (fr) 2002-03-21

Similar Documents

Publication Publication Date Title
US5693654A (en) Medicaments for treating intraocular pressure
JP2008523102A (ja) Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
EP1420790A1 (fr) Utilisation de bibn4096 en combinaison avec d'autres medicaments contre la migraine pour le traitement de la migraine
US20030004126A1 (en) Formulations of adenosine A1 agonists
US20030018031A1 (en) Formulations of 5HT agonists
EP1235576A2 (fr) Combinaisons de sumatriptan ou de naratriptan avec l'inhibiteur de cyclooxygenase ii
CA2537748A1 (fr) Utilisation de telmisartan pour la prevention de la cephalee vasculaire
RU2160101C2 (ru) Средство для лечения десинхронизационных нарушений, фармацевтическая композиция
IL99715A (en) Pharmaceutical preparations containing a history of indulgence are used
EP1239882B1 (fr) Formulations d'agonistes adenosine a1 et d'agonistes de 5ht3
CA2345248C (fr) Utilisation d'antagonistes de prostanoides pour le traitement de cephalees primaires
EP0876146B1 (fr) Analogues de nucleosides utilises dans une therapie combinee contre des infections dues a l'herpes simplex
EP1239878B1 (fr) Formulations d'agonistes de l'adenosine a1 et d'agonistes de 5ht1
WO2001045683A2 (fr) Formulations d'agonistes de l'adenosine a1
EP0433043A1 (fr) Médicaments
WO1997033579A1 (fr) Medicaments comprenant des agonistes du recepteur de type 5ht1 presentant une meilleure absorption
EP1545511B1 (fr) Utilisation combinee de methylphenidate et de melatonine pour le traitement d'un trouble d'hyperactivite avec deficience de l'attention
MXPA02009811A (es) Combinacion de farmaco para el tratamiento de dolor de cabeza que comprende un farmaco no esteroidal anti-inflamatorio.
US20020198170A1 (en) Formulations of adenosine a1 agonists
CA2244268C (fr) Analogues de nucleosides utilises dans une therapie combinee contre des infections dues a l'herpes simplex
AU2002333393A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
HK1016475B (en) Nucleoside analogs in combination therapy of herpes simplex infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020524

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050118